/ /

Cheryl Guttman Krader
Laser still useful diabetic eye disease tool in anti-VEGF era
Although clinical trial results have advanced anti-VEGF injections to the forefront of treatment for diabetic eye disease, laser photocoagulation continues to be an important modality for the management of diabetic macular edema (DME) and diabetic retinopathy (DR), said Elias Reichel, MD, at the inaugural Retina World Congress.
Epiretinal prosthesis life-changing for some RP patients
Implantation of a retinal prosthesis system (Argus II, Second Sight Medical Systems) in patients with retinitis pigmentosa (RP) is safe and is providing some encouraging results when considered from the recipient’s perspective. Careful patient selection, however, is important and should consider the need for compliance with an intensive postoperative rehabilitation process, said Stanislao Rizzo, MD, at the inaugural Retina World Congress.
Effective drug management of PVR remains unfulfilled goal
The bottom line about pharmaceutical management of proliferative vitreoretinopathy (PVR) is that many different drugs have been tried, but so far nothing has been proven effective for treating PVR or reducing its risk, said Demetrios G. Vavvas, MD, PhD, at the inaugural Retina World Congress.
Transplantable 3-D retinas
Transplantable 3-D retinas
AIVITA Biomedical has successfully engineered a three-dimensional transplantable retina construct and demonstrated connectivity and conductivity in an animal model of retinal degeneration.
Data support adding suprachoroidal injection to anti-VEGF for RVO
Results from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
Crosslinking showing potential for refractive correction
Crosslinking showing potential for refractive correction
Photorefractive intrastromal cross-linking is being developed for non-invasive correction of low refractive errors.
Improving the prognosis of uveal melanoma
About one-half of people diagnosed with uveal melanoma ultimately develop metastatic disease. A look at survival rates for patients with uveal melanoma indicate that not much has changed in the past several decades or even for the past 100-plus years. Nevertheless, there is good reason to be optimistic about the future considering the recent developments and ongoing research in this field, said Mary Beth Aronow, MD, at Ocular Oncology and Pathology 2016.
Weighing IOP fluctuation in glaucoma progression
Available evidence indicates that long-term IOP fluctuation is an important factor in glaucoma progression, said Joseph Caprioli, MD. Based on this information he encouraged ophthalmologists to consider IOP “modulation” rather than “reduction.”
Looking to long-range keratoprosthesis outcomes
Findings from a single-surgeon consecutive series including 97 eyes with up to 12 years of follow-up provide realistic insights for corneal surgeons about long-term outcomes after implantation of the Boston keratoprosthesis type 1 (“Boston KPro”; Massachusetts Eye and Ear Infirmary). The information—which included analyses of visual acuity results, device retention rates, and complications associated with the permanent keratoprosthesis—was presented by Anthony J. Aldave, MD, at Cornea 2016.

Poll

View Results